CSPC's SYS6043 Phase I/II Breast Cancer Data Presented at ESMO: ORR Exceeds 50% Across All Three Subtypes
nashnova research
CSPC Pharmaceutical (01093) unveiled full Phase I/II breast cancer data for its B7-H3-targeting ADC SYS6043 at the ESMO annual meeting — objective response rates topped 50% in all three subtypes, while interstitial lung disease sat at just 1.4%. This means → the drug cleared a meaningful early-stage bar on both efficacy and safety; the pace of registrational trial design now becomes the key catalyst.
What did this study actually test?
SYS6043 is an ADC — antibody-drug conjugate, a guided missile that straps a chemo "warhead" onto an antibody so the drug homes in on tumor cells — targeting B7-H3.
The Phase I/II trial enrolled 139 patients with advanced breast cancer across three subtypes: HR+/HER2- (84), triple-negative (32), and HER2+ (23). Median age was 54; most had already been through multiple lines of therapy.
This means → these are heavily pre-treated, hard-to-move patients. Showing activity here sets a higher bar than a frontline trial would.
How did the three subtypes respond?
HR+/HER2- (largest group, 82 evaluable): confirmed ORR — the share of patients whose tumors shrank significantly — was 53.7%, DCR 92.7%. At a median follow-up of roughly five months, median duration of response and median PFS had not yet been reached. In plain terms = the drug is still working; the data have not peaked.
Triple-negative breast cancer (TNBC, 32 patients): ORR hit 75.0%, DCR 93.8%, median PFS 7.2 months, median DoR 5.5 months. This reflects standout tumor-shrinkage activity in the historically hardest-to-treat subtype.
HER2+ (23 patients): ORR 69.6%, DCR 95.7%, median DoR 7.0 months, median PFS not reached. All three subtypes clearing 50% ORR is a strong showing for early-stage ADC data.
Is the safety profile clean enough?
Across all 139 dosed patients, treatment-related adverse events (TRAEs) occurred in 99.3%. In plain terms = nearly everyone had side effects, but that is standard for chemo-class drugs — severity is what matters.
Grade ≥3 TRAEs ran at 28.8%; serious TRAEs at just 5.8%. The most common were nausea (61.2%), leukopenia (60.4%), neutropenia (55.4%), anemia and fatigue (each ~51%).
Only 1 patient (0.7%) discontinued due to side effects; there were zero treatment-related deaths. Interstitial lung disease — the ADC-class risk the market watches most closely — came in at just 1.4%. This means → ILD risk sits at the low end among peer ADCs, a positive signal for the safety envelope of larger trials ahead.
What makes the target and drug design noteworthy?
B7-H3 is broadly expressed across breast cancers. The wider the expression, the more tumor cells the ADC can reach — that is the core rationale for choosing this target.
SYS6043 pairs a cleavable linker (releases the warhead once inside the tumor) with an Fc-gamma-receptor-silenced backbone (reduces off-target immune toxicity) and a topoisomerase-I inhibitor payload. Its DAR — drug-to-antibody ratio, the number of warheads per antibody — is roughly 6.
This means → the drug also carries a bystander effect: even neighboring cells that do not express B7-H3 can be killed by the released payload. That matters most in heterogeneous solid tumors.
What comes next?
CSPC confirmed it will advance further studies at 6 mg/kg every three weeks (Q3W), signaling that dose exploration is essentially complete.
This means → the next key catalyst is the timing and design of a registrational trial — that will determine how quickly SYS6043 moves from "promising data" to "path to approval."
In plain terms = the early data have cleared the "is this worth pursuing" hurdle. The question now is how fast CSPC can push it to the finish line.
市场有风险，内容仅供研究参考，不构成投资建议。